Terms: = Ovarian cancer AND MLH1, COCA2, 4292, ENSG00000076242, hMLH1, FCC2, HNPCC2, P40692, MGC5172, HNPCC AND Clinical Outcome
11 results:
1. Corded and Hyalinized Endometrioid Adenocarcinoma (CHEC) of the Uterine Corpus are Characterized by CTNNB1 Mutations and Can Show Adverse clinical outcomes.
Ladwig NR; Umetsu SE; Zaloudek C; Rabban J; Garg K
Int J Gynecol Pathol; 2021 Mar; 40(2):103-115. PubMed ID: 32909971
[TBL] [Abstract] [Full Text] [Related]
2. Genetic polymorphisms in
Si W; Kang S; Sun H; Chen J; Cao S; Li Y
Int J Gynecol Cancer; 2019 Sep; 29(7):1148-1155. PubMed ID: 31273068
[TBL] [Abstract] [Full Text] [Related]
3. Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups.
Parra-Herran C; Lerner-Ellis J; Xu B; Khalouei S; Bassiouny D; Cesari M; Ismiil N; Nofech-Mozes S
Mod Pathol; 2017 Dec; 30(12):1748-1759. PubMed ID: 28776572
[TBL] [Abstract] [Full Text] [Related]
4. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
Ogino S; Lochhead P; Giovannucci E; Meyerhardt JA; Fuchs CS; Chan AT
Oncogene; 2014 Jun; 33(23):2949-55. PubMed ID: 23792451
[TBL] [Abstract] [Full Text] [Related]
5. Clinicopathological and molecular characterization of colorectal micropapillary carcinoma.
Verdú M; Román R; Calvo M; Rodón N; García B; González M; Vidal A; Puig X
Mod Pathol; 2011 May; 24(5):729-38. PubMed ID: 21336262
[TBL] [Abstract] [Full Text] [Related]
6. Pharmaco(epi)genomics in ovarian cancer.
Paige AJ; Brown R
Pharmacogenomics; 2008 Dec; 9(12):1825-34. PubMed ID: 19072641
[TBL] [Abstract] [Full Text] [Related]
7. BRCA1 promoter methylation predicts adverse ovarian cancer prognosis.
Chiang JW; Karlan BY; Cass L; Baldwin RL
Gynecol Oncol; 2006 Jun; 101(3):403-10. PubMed ID: 16360812
[TBL] [Abstract] [Full Text] [Related]
8. Hereditary ovarian cancer.
Prat J; Ribé A; Gallardo A
Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
[TBL] [Abstract] [Full Text] [Related]
9. Loss of hmlh1 expression correlates with improved survival in stage III-IV ovarian cancer patients.
Scartozzi M; De Nictolis M; Galizia E; Carassai P; Bianchi F; Berardi R; Gesuita R; Piga A; Cellerino R; Porfiri E
Eur J Cancer; 2003 May; 39(8):1144-9. PubMed ID: 12736115
[TBL] [Abstract] [Full Text] [Related]
10. Hereditary risk of women's cancers.
Frank TS; Critchfield GC
Best Pract Res Clin Obstet Gynaecol; 2002 Oct; 16(5):703-13. PubMed ID: 12475549
[TBL] [Abstract] [Full Text] [Related]
11. Microsatellite instability in gynecological sarcomas and in hMSH2 mutant uterine sarcoma cell lines defective in mismatch repair activity.
Risinger JI; Umar A; Boyer JC; Evans AC; Berchuck A; Kunkel TA; Barrett JC
Cancer Res; 1995 Dec; 55(23):5664-9. PubMed ID: 7585651
[TBL] [Abstract] [Full Text] [Related]
